Menu
Back to User profile » Dr Haiquan Chen
Papers published by Dr Haiquan Chen:
Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Yu H, Sun S, Hu X, Xia J, Wang J, Chen H
OncoTargets and Therapy 2019, 12:6481-6495
Published Date: 14 August 2019
ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature
Zheng Q, Zheng M, Jin Y, Shen X, Shan L, Shen L, Sun Y, Chen H, Li Y
OncoTargets and Therapy 2018, 11:4991-4998
Published Date: 17 August 2018
The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive
Yu S, Zhang Y, Pan YJ, Cheng C, Sun YH, Chen HQ
OncoTargets and Therapy 2017, 10:4507-4515
Published Date: 12 September 2017
The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
Zheng DF, Wang R, Zhang Y, Pan YJ, Cheng XH, Cheng C, Zheng SB, Li H, Gong RX, Li Y, Shen XX, Sun YH, Chen HQ
OncoTargets and Therapy 2016, 9:833-843
Published Date: 22 February 2016
Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension
Zhang Y, Sun Y, Chen H
OncoTargets and Therapy 2016, 9:649-653
Published Date: 5 February 2016
Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review
Zhang J, Wang SF, Wang L, Wang R, Chen SF, Pan B, Sun YH, Chen HQ
OncoTargets and Therapy 2015, 8:3361-3369
Published Date: 18 November 2015
HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma
Pan B, Wang R, Huang YL, Garfield D, Zhang J, Chen HQ
OncoTargets and Therapy 2015, 8:1185-1191
Published Date: 25 May 2015
Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma
Cai D, Li H, Wang R, Li Y, Pan YJ, Hu HC, Zhang Y, Gong RX, Pan B, Sun YH, Chen HQ
OncoTargets and Therapy 2014, 7:2127-2132
Published Date: 18 November 2014
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
Cheng X, Chen H
OncoTargets and Therapy 2014, 7:1689-1704
Published Date: 23 September 2014
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma
Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H
OncoTargets and Therapy 2014, 7:1423-1437
Published Date: 13 August 2014
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H
OncoTargets and Therapy 2014, 7:567-573
Published Date: 12 April 2014
Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, Zhang Y, Ye T, Zhang Y, Li B, Shen L, Sun Y, Chen H
OncoTargets and Therapy 2014, 7:513-524
Published Date: 3 April 2014